Study Finds No Significant Benefits of Mavacamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy
A large phase III trial reveals that mavacamten does not significantly improve symptoms or exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, highlighting the need for new therapeutic strategies.
Recent research presented at ESC Congress 2025 and published in the New England Journal of Medicine has shown that mavacamten, a cardiac myosin inhibitor, does not provide significant improvements in health status or exercise capacity for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). The phase III ODYSSEY-HCM trial involved 580 adult patients across 22 countries, all experiencing symptoms consistent with nonobstructive HCM, a condition characterized by thickening of the heart muscle without significant blood flow obstruction. Participants were randomly assigned to receive either mavacamten or a placebo over a 48-week period.
The primary measures of the study were changes in patient-reported health status, evaluated by the Kansas City Cardiomyopathy Questionnaire 23-item Clinical Summary Score (KCCQ-23 CSS), and peak oxygen consumption during exercise. Results indicated no statistically significant differences between the mavacamten and placebo groups in these parameters. The average increase in quality of life scores was modest and statistically borderline, and there was no notable improvement in exercise capacity.
Safety assessments revealed that mavacamten was associated with a higher incidence of treatment-emergent adverse events, including reductions in left ventricular ejection fraction below 50%, which occurred in over 21% of the mavacamten group but in less than 2% of the placebo group. Most cases of reduced ejection fraction improved back to normal after treatment interruption.
Professor Milind Desai explained that these findings suggest mavacamten does not currently benefit patients with nonobstructive HCM, despite previous promising small-scale studies. Further analyses are underway to identify whether specific subgroups may derive benefit from this therapy. Overall, the trial emphasizes the need for ongoing research to develop effective treatments for this patient population.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Photoacoustic Contrast Agent Enhances Tumor Imaging Safety and Cost-Effectiveness
A new biocompatible contrast agent for photoacoustic tomography offers an safer and cost-effective alternative for tumor imaging, reducing reliance on expensive and radiation-based techniques like PET.
Limited Effectiveness of Emergency Health Messaging on Social Media Platforms
A recent study highlights the limitations of social media in emergency health communication, emphasizing the need for more interactive and multilingual approaches during health crises.
Cholesterol Drug Repurposed to Improve Blood-Brain Barrier and Neuropsychiatric Outcomes in DiGeorge Syndrome
Research reveals that cholesterol-lowering drugs may restore mitochondrial function and improve blood-brain barrier integrity, offering new hope for neuropsychiatric conditions in DiGeorge syndrome.
Enhanced Survival in BRAF V600E-Mutated Metastatic Colorectal Cancer Using Triple Therapy
A groundbreaking Phase III trial shows that combining encorafenib, cetuximab, and chemotherapy significantly prolongs survival in patients with BRAF V600E-mutated metastatic colorectal cancer, marking a major advancement in personalized cancer therapy.